MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

Core Viewpoint - MiNK Therapeutics, Inc. is set to release its first quarter 2025 financial results on May 15, 2025, and will host a conference call to discuss these results and provide a corporate update [1]. Group 1: Company Overview - MiNK Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases [3]. - The company is advancing a pipeline of both native and next-generation engineered iNKT programs, emphasizing scalable and reproducible manufacturing for off-the-shelf delivery [3]. - MiNK Therapeutics is headquartered in New York, NY, and provides regular updates on important information for investors through its website and social media channels [3]. Group 2: Conference Call Details - The conference call will take place on May 15, 2025, at 8:30 a.m. ET, following the release of the financial results [1]. - Dial-in numbers for the conference call include 646-307-1963 for New York and 800-715-9871 for USA & Canada, with a conference ID of 9822477 [2]. - A live webcast and replay of the conference call will be available on the company's Events & Presentations page [2].